Peringatan Keamanan

Data regarding overdoses of amivantamab are not readily available.L34193 Patients experiencing an overdose should be treated with symptomatic and supportive measures.

Amivantamab

DB16695

biotech approved investigational

Deskripsi

Amivantamab, also known as JNJ-61186372, is an anti-EGFR-MET bispecific antibody, derived from Chinese hamster ovary cells, approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.A235103,L34193 Patients with NSCLC often develop resistance to drugs that target EGFR and MET individually, so amivantamab was developed to attack both targets, reducing the chance of resistance developing.A235103,A235118 Amivantamab was found to be more effective than the EGFR inhibitor erlotinib or the MET inhibitor crizotinib in vivo.A235103,A235123 Patients with NSCLC with exon 20 insertion mutations in EGFR do not respond to tyrosine kinase inhibitors, and were generally treated with platinum-based therapy.A235133

Amivantamab was granted FDA approval on 21 May 2021,L34193 followed by the approval by the EMA on 9 December 2021 L41474 and Health Canada on 30 March 2022.L41469

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The terminal half life of amivantamab-vmjw is 11.3 ± 4.53 days.[L34193]
Volume Distribusi The mean volume of distribution of amivantamab-vmjw is 5.13 ±1.78 L.[L34193]
Klirens (Clearance) The mean clearance of amivantamab-vmjw is 360 ± 144 mL/day.[L34193]

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Antibodies are expected to be metabolized to oligopeptides and amino acids.A40006

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

372 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Amivantamab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Amivantamab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Amivantamab.
Estrone Estrone may increase the thrombogenic activities of Amivantamab.
Estradiol Estradiol may increase the thrombogenic activities of Amivantamab.
Dienestrol Dienestrol may increase the thrombogenic activities of Amivantamab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Amivantamab.
Mestranol Mestranol may increase the thrombogenic activities of Amivantamab.
Estriol Estriol may increase the thrombogenic activities of Amivantamab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Amivantamab.
Quinestrol Quinestrol may increase the thrombogenic activities of Amivantamab.
Hexestrol Hexestrol may increase the thrombogenic activities of Amivantamab.
Tibolone Tibolone may increase the thrombogenic activities of Amivantamab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Amivantamab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Amivantamab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Amivantamab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Amivantamab.
Zeranol Zeranol may increase the thrombogenic activities of Amivantamab.
Equol Equol may increase the thrombogenic activities of Amivantamab.
Promestriene Promestriene may increase the thrombogenic activities of Amivantamab.
Methallenestril Methallenestril may increase the thrombogenic activities of Amivantamab.
Epimestrol Epimestrol may increase the thrombogenic activities of Amivantamab.
Moxestrol Moxestrol may increase the thrombogenic activities of Amivantamab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Amivantamab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Amivantamab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Amivantamab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Amivantamab.
Biochanin A Biochanin A may increase the thrombogenic activities of Amivantamab.
Formononetin Formononetin may increase the thrombogenic activities of Amivantamab.
Estetrol Estetrol may increase the thrombogenic activities of Amivantamab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Amivantamab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Amivantamab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Amivantamab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Amivantamab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Amivantamab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Amivantamab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Amivantamab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Amivantamab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Amivantamab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Amivantamab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Amivantamab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Amivantamab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Amivantamab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Amivantamab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Amivantamab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Amivantamab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Amivantamab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Amivantamab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Amivantamab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Amivantamab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Amivantamab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Amivantamab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Amivantamab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Amivantamab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Amivantamab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Amivantamab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Amivantamab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Amivantamab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Amivantamab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Amivantamab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Amivantamab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Amivantamab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Amivantamab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Amivantamab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Amivantamab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Amivantamab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Amivantamab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Amivantamab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Amivantamab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Amivantamab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Amivantamab.
Hepatitis B immune globulin The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Amivantamab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Amivantamab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Amivantamab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Amivantamab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Amivantamab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Amivantamab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Amivantamab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Amivantamab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Amivantamab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Amivantamab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Amivantamab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Amivantamab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Amivantamab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Amivantamab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Amivantamab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Amivantamab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Amivantamab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Amivantamab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Amivantamab.
Stamulumab The risk or severity of adverse effects can be increased when MYO-029 is combined with Amivantamab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Amivantamab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Amivantamab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Amivantamab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Amivantamab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Amivantamab.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Amivantamab.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Amivantamab.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Amivantamab.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Amivantamab.

Target Protein

Epidermal growth factor receptor EGFR
Hepatocyte growth factor receptor MET
Low affinity immunoglobulin gamma Fc region receptor III-A FCGR3A

Referensi & Sumber

Artikel (PubMed)
  • PMID: 33839159
    Neijssen J, Cardoso RMF, Chevalier KM, Wiegman L, Valerius T, Anderson GM, Moores SL, Schuurman J, Parren PWHI, Strohl WR, Chiu ML: Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. J Biol Chem. 2021 Apr 8:100641. doi: 10.1016/j.jbc.2021.100641.
  • PMID: 26260789
    Jarantow SW, Bushey BS, Pardinas JR, Boakye K, Lacy ER, Sanders R, Sepulveda MA, Moores SL, Chiu ML: Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor x c-MET Bispecific Antibody. J Biol Chem. 2015 Oct 9;290(41):24689-704. doi: 10.1074/jbc.M115.651653. Epub 2015 Aug 10.
  • PMID: 27216193
    Moores SL, Chiu ML, Bushey BS, Chevalier K, Luistro L, Dorn K, Brezski RJ, Haytko P, Kelly T, Wu SJ, Martin PL, Neijssen J, Parren PW, Schuurman J, Attar RM, Laquerre S, Lorenzi MV, Anderson GM: A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors. Cancer Res. 2016 Jul 1;76(13):3942-53. doi: 10.1158/0008-5472.CAN-15-2833. Epub 2016 May 23.
  • PMID: 27786612
    Grugan KD, Dorn K, Jarantow SW, Bushey BS, Pardinas JR, Laquerre S, Moores SL, Chiu ML: Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells. MAbs. 2017 Jan;9(1):114-126. doi: 10.1080/19420862.2016.1249079. Epub 2016 Oct 27.
  • PMID: 33946594
    Metro G, Baglivo S, Bellezza G, Mandarano M, Gili A, Marchetti G, Toraldo M, Molica C, Reda MS, Tofanetti FR, Siggillino A, Prosperi E, Giglietti A, Di Girolamo B, Garaffa M, Marasciulo F, Minotti V, Gunnellini M, Guida A, Sassi M, Sidoni A, Roila F, Ludovini V: Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations. Genes (Basel). 2021 Apr 30;12(5). pii: genes12050679. doi: 10.3390/genes12050679.
  • PMID: 32414908
    Yun J, Lee SH, Kim SY, Jeong SY, Kim JH, Pyo KH, Park CW, Heo SG, Yun MR, Lim S, Lim SM, Hong MH, Kim HR, Thayu M, Curtin JC, Knoblauch RE, Lorenzi MV, Roshak A, Cho BC: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209. doi: 10.1158/2159-8290.CD-20-0116. Epub 2020 May 15.
  • PMID: 32747419
    Vijayaraghavan S, Lipfert L, Chevalier K, Bushey BS, Henley B, Lenhart R, Sendecki J, Beqiri M, Millar HJ, Packman K, Lorenzi MV, Laquerre S, Moores SL: Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis. Mol Cancer Ther. 2020 Oct;19(10):2044-2056. doi: 10.1158/1535-7163.MCT-20-0071. Epub 2020 Aug 3.
  • PMID: 28653357
    Ryman JT, Meibohm B: Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):576-588. doi: 10.1002/psp4.12224. Epub 2017 Jul 29.

Contoh Produk & Brand

Produk: 3 • International brands: 1
Produk
  • Rybrevant
    Solution • 350 mg / 7 mL • Intravenous • Canada • Approved
  • Rybrevant
    Injection • 350 mg/1 • Intravenous • US • Approved
  • Rybrevant
    Injection, solution, concentrate • 350 mg • Intravenous • EU • Approved
International Brands
  • Rybrevant — Janssen Pharmaceutical Companies of Johnson & Johnson

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul